Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 141-146

  Wood, William A ^a   Whitley, Julia ^a   Moore, Dominic ^a   Sharf, Andrew ^a   Irons, Robert ^a   Rao, Kamakshi ^a   Serody, Jonathan ^a   Coghill, Jay ^a   Gabriel, Donald ^a   Shea, Thomas ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Autologous stem cell transplantation; Etoposide; Lenalidomide; Myeloma; Stem cell mobilization

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; ONDANSETRON; PROCHLORPERAZINE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL POPULATION; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; RECURRENCE FREE SURVIVAL; STEM CELL MOBILIZATION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VOMITING; AGE; APHERESIS; AUTOTRANSPLANTATION; CELL COUNT; CYTOLOGY; HEMATOPOIETIC STEM CELL; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD COMPONENT REMOVAL; CELL COUNT; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 79956221715     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.021     Document Type: Article

References (26)

1. Pasquini MC, He V, Perez WS. CIBMTR summary slides part 1. CIBMTR Newslett. 2006;12:5-7.
2. Shea TC, DiPersio JF. Mobilization of autologous peripheral blood hematopoietic cells for cellular therapy. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas' Hematopoietic Cell Transplantation, 4th ed. Boston: Blackwell Publishing; 2009.
3. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43:181-195.
4. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol. 1995;13:2547-2555.
5. Giralt S, Statdtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904-1912.
6. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114: 1729-1735.
7. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720-5726.
8. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008;22:1280-1281. author reply: 1281-1282.
9. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastiminduced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718-723.
10. Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997;20:211-217.
11. Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocytemacrophage-colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2004;10:395-404.
12. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy. 2007;9:539-547.
13. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14:795-798.
14. Gertz MA, Kumar SK, Lazy MQ, et al. Comparison of highdose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619-625.
15. Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following 2 different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplantat. 2001;27:837-842.
16. Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion. 2007;47:629-635.
17. Gianni AM, Bregni M, Siena S, et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol. 1992;10:1955-1962.
18. Bandarenko N, Sims LC, Brecher ME. Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields. Transfusion. 1997;37:1218. author reply 1218-1220.
19. Kobbe G, Sohngen D, Bauser U, et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients withmalignant lymphoma and multiple myeloma. Ann Hematol. 1999;78:456-462.
20. De la Rubia J, Blade J, Lahuerta JJ, et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica. 2006;91:621-627.
21. Perea G, Sureda A, Martino R, et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol. 2001;80:592-597.
22. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035-2042.
23. Copelan EA, Ceseslski SK, Ezzone SA, et al. Mobilization of peripheral blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol. 1997;15:759-765.
24. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapyrelated leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95(5):1588-1593.
25. Copelan E, Hoshaw-Woodard S, Elder P, et al. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant. 2004;34:85-87.
26. Qazilbash MH, Giralt SA. Hematopoietic cell transplantation for multiple myeloma. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KS, editors. Thomas' Hematopoietic Cell Transplantation, 4th ed. Boston: Blackwell Publishing; 2009